Clinical Scorecard: Clinical and Imaging Features of Intracerebral Hemorrhage Associated with Brain Tumors and Metastatic Lesions

At a Glance

Key Highlights

• Neoplastic ICH is clinically challenging to distinguish from hypertensive or other non-neoplastic ICH, leading to potential delays in diagnosis and treatment.
• Distinct clinical and radiographic features may differentiate ICH associated with primary brain tumors from metastatic lesions.
• Quantitative imaging and detailed clinical characterization improve diagnostic accuracy and patient management.

Guideline-Based Recommendations

Diagnosis

• Use the H-ATOMIC Classification system to categorize etiology of occult acute ICH.
• Exclude other causes such as hypertension, cerebral amyloid angiopathy, coagulopathies, vascular malformations, trauma, and hemorrhagic transformation post-ischemic stroke.
• Employ advanced imaging including CT and follow-up MRI to detect underlying neoplastic lesions masked by hemorrhage.

Management

• Consider prior therapies such as craniotomy, chemo-, immunotherapy, radiotherapy, and steroid treatment in management planning.
• Monitor and manage vascular risk factors and pre-existing anticoagulation or antiplatelet therapies.
• Tailor treatment based on tumor type (primary vs metastatic) and hemorrhage characteristics.

Monitoring & Follow-up

• Assess Glasgow Coma Scale (GCS) at admission and modified Rankin Scale (mRS) at discharge or last evaluation to monitor neurological status and functional outcome.
• Perform volumetric quantification of ICH and perihematomal edema on imaging.
• Evaluate for secondary intraventricular hemorrhage and hemorrhage location to guide prognosis and treatment.

Risks

• Delayed diagnosis due to difficulty distinguishing neoplastic ICH from other hemorrhagic etiologies.
• High mortality associated with neoplastic ICH.
• Potential masking of underlying tumor by hemorrhage on initial imaging.

Patient & Prescribing Data

Patients with intracerebral hemorrhage secondary to primary brain tumors or metastatic brain lesions

Prior use of anticoagulants, antiplatelet agents, and therapies such as steroids, chemo-, immuno-, and radiotherapy influence clinical presentation and management strategies.

Clinical Best Practices

• Perform comprehensive clinical assessment including neurological deficits, seizures, cognitive impairment, and systemic symptoms.
• Use detailed imaging protocols to localize hemorrhage and identify tumor type.
• Dichotomize mRS scores to evaluate functional independence versus need for assistance.
• Integrate clinical, imaging, and treatment history for accurate diagnosis and timely intervention.

References

• Central nervous system tumors and metastases mortality data
• H-ATOMIC Classification system for ICH etiology
• Imaging and volumetric quantification of ICH and perihematomal edema